Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Learn more: To view or add a comment, sign in 1,669 followers Explore related topics Trends in Glp-1 Treatment Options Trends in Weight Loss Drug Accessibility Impact of Glp-1 Medications on Health How New Techniques Improve Patient Outcomes Advancements in Diabetes and Obesity Treatments How Glp-1 Drugs Impact Economic Trends Trends in Weight Management Solutions How to Align Innovation with Patient Needs Latest Strategies for Diabetes Management Latest Developments in Type 1 Diabetes Research
Ecnoglutide's biased GLP-1 signaling represents a scientifically novel approach, and SLIMMER Phase 3 data (15.4% weight loss at 48 weeks) are comparable to semaglutide's STEP 1 results (14.9% at 68 weeks)
Are there assistance programs or generic versions available
Note that 2/3 of the weight lost by the participants was regained within a year of stopping treatment with semaglutide
